MedTrace Logo

Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD

NCT01213667 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2016-10-26

No results posted yet for this study

Summary

To assess genetic features and intraocular cytokine profiles of non-responders to anti-VEGF treatment of exudative age-related macular degeneration. Also to assess necessity and frequency of pro re nate medical re-treatment.

Conditions

  • Macular Degeneration

Interventions

DRUG

Ranibizumab

upload (three monthly injections), re-treatment as needed

Sponsors & Collaborators

  • University of Cologne

    lead OTHER

Principal Investigators

  • Philipp S Muether, MD · Center of Ophthalmology, University of Cologne

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01213667 on ClinicalTrials.gov